Chase LoPriore
CIK: 0002136903
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)2 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
HEPA
Hepion Pharmaceuticals, Inc.
DirectorOfficer
Discretionary Trading P&L
Holdings
About LoPriore Chase
LoPriore Chase (SEC CIK 0002136903) files insider reports with the SEC as VP, Corp. Dev. of Hepion Pharmaceuticals, Inc. (HEPA).
Signal8 holds 3 ownership filings by LoPriore Chase (1 Form 3, 2 Form 4), filed between May 26, 2026 and Oct 27, 2026. Those filings report 2 transactions, from Aug 19, 2026 to Oct 23, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on LoPriore Chase's filings is in RED BANK, NJ.
Recent filings by LoPriore Chase
Other insiders filing for Hepion Pharmaceuticals, Inc. (HEPA)
- Liddy James Gordon, Director
- Fisher Danina, Director
- Stetz Gary S., Chief Financial Officer
- LoPriore Vincent S, Executive Chairman
- Purcell Michael J., Director
- Appajosyula Sireesh, Chief Executive Officer